C2 Blockchain (CBLO) details small private stock financings

Rhea-AI Filing Summary

C2 Blockchain, Inc. reported two recent private sales of its common stock to accredited investors. Around September 10, 2025, the company issued 750,000 restricted shares at $0.02 per share, raising gross proceeds of $15,000. Around October 3, 2025, it issued a further 10,000,000 restricted shares at $0.01 per share, for gross proceeds of $100,000, referred to as the First Tranche.

The October subscription agreement also allows an optional Second Tranche of 10,000,000 additional shares at $0.01 per share for another $100,000, at the investor’s sole discretion on or before October 17, 2025; only the First Tranche has been funded so far. The shares carry transfer restrictions and legends, and no underwriting discounts, commissions, or finder’s fees were paid. The company plans to use the cash for general corporate purposes and working capital, and relied on Section 4(a)(2) and Rule 506(b) of Regulation D for exemption from registration.

false 0001882781 0001882781 2025-09-10 2025-09-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 10, 2025

C2 Blockchain, Inc.

(Exact name of registrant as specified in its charter)

NV	000-56340	87-2645378
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

12818 SW 8th St Unit #2008

Miami, FL 33184

(Address of principal executive offices)

888-437-3432

(Registrant’s telephone number, including area code)

________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).    ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐ 

Unless otherwise indicated or the context otherwise requires, references in this report to “we,” “us,” “our,” “C2 Blockchain,” or the “Company” refer to C2 Blockchain, Inc.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K may contain forward-looking statements, including statements regarding the intended use of proceeds from the private placements (described below) and the Company’s future plans and expectations. These statements are based on current beliefs and assumptions and are subject to various risks and uncertainties, many of which are beyond the Company's control. Actual results may differ materially from those anticipated or implied in any forward-looking statements. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update or revise any such statements, except as required by applicable law, including the Securities Act of 1933 and the Securities Exchange Act of 1934.

Item 3.02 Unregistered Sales of Equity Securities

On or about September 10, 2025, the Company entered into a subscription agreement with an accredited investor pursuant to which it issued 750,000 shares of its restricted common stock at a purchase price of $0.02 per share, for gross proceeds of $15,000.

On or about October 3, 2025, the Company entered into a subscription agreement with an accredited investor pursuant to which it issued 10,000,000 shares of its restricted common stock at a purchase price of $0.01 per share, for gross proceeds of $100,000 (the “First Tranche”). The subscription agreement also provides for an optional second tranche of 10,000,000 shares at the same purchase price for additional proceeds of $100,000, which may be funded by the investor on or before October 17, 2025, at the investor’s sole discretion. As of the date of this Report, only the First Tranche has been funded and shares issued.

For each of the foregoing transactions, the dates cited above reflect the dates of the subscription agreements and not necessarily the dates on which investor funds were received or the shares were actually issued. In all cases, the shares were issued subsequent to the dates of the subscription agreements. Each investor represented that the securities were being acquired for investment purposes and not with a view to distribution. The shares are subject to transfer restrictions and bear a restrictive legend. No underwriting discounts, commissions, or placement agent or finder’s fees were paid in connection with the transactions. The Company intends to use the proceeds for general corporate purposes and working capital.

The issuances were made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) of Regulation D thereunder, based on the nature of the offerings and the representations made by the investors regarding their accredited investor status. The offerings did not involve any public offering or general solicitation and were conducted as private transactions.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

C2 Blockchain, Inc.

Dated: October 7, 2025

By: /s/ Levi Jacobson

Levi Jacobson

Chief Executive Officer

-3- 

FAQ

What private placements did C2 Blockchain (CBLO) recently complete?

C2 Blockchain completed two private sales of restricted common stock to accredited investors: 750,000 shares at $0.02 per share and 10,000,000 shares at $0.01 per share.

How much cash did C2 Blockchain (CBLO) raise in these private stock sales?

The company raised gross proceeds of $15,000 from the 750,000-share issuance and $100,000 from the 10,000,000-share First Tranche, for total gross proceeds of $115,000.

Is there an additional optional tranche in C2 Blockchain’s (CBLO) financing?

Yes. The October 3, 2025 subscription agreement includes an optional Second Tranche of 10,000,000 shares at $0.01 per share for additional gross proceeds of $100,000, which may be funded by the investor on or before October 17, 2025, at the investor’s sole discretion. As of the report date, only the First Tranche has been funded.

What are the terms of the shares issued in C2 Blockchain’s (CBLO) private placements?

The issued shares are restricted common stock, acquired for investment purposes, subject to transfer restrictions and bearing a restrictive legend. No underwriting discounts, commissions, placement agent fees, or finder’s fees were paid.

How does C2 Blockchain (CBLO) intend to use the proceeds from these private placements?

The company intends to use the gross proceeds from the private stock issuances for general corporate purposes and working capital.

Under what securities law exemptions were C2 Blockchain’s (CBLO) share issuances made?

The share issuances were made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D, with no public offering or general solicitation.